Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nilvanstomig + paclitaxel + platinum chemotherapy
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of ZG005 (nilvanstomig), paclitaxel, and platinum chemotherapy is an investigational chemo-immunotherapy regimen being evaluated for the first-line treatment of advanced solid tumors, particularly advanced cervical cancer. Nilvanstomig is a recombinant humanized bispecific antibody designed to simultaneously target and block the PD-1 and TIGIT immune checkpoint pathways, thereby synergistically restoring T-cell and NK-cell mediated anti-tumor immune responses. Paclitaxel is a microtubule-stabilizing chemotherapy agent that inhibits cell division, while the platinum component (either cisplatin or carboplatin) acts as a DNA-damaging alkylating agent. By combining dual checkpoint inhibition with cytotoxic chemotherapy, this regimen aims to enhance immunogenic cell death and improve clinical outcomes in patients with advanced malignancies.
- Other names
- ZG005 + paclitaxel + carboplatinZG005 + paclitaxel + cisplatinZG005 + paclitaxel + platinum chemotherapynilvanstomig + paclitaxel + carboplatinnilvanstomig + paclitaxel + cisplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nilvanstomig + paclitaxel + platinum chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nilvanstomig + paclitaxel + platinum chemotherapy.